A Phase 2 interventional study of CM338 in IgA Nephropathy, sponsored by Keymed Biosciences Co.Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Keymed Biosciences Co.Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Glomerulonephritis, IGA with a site in China — 57 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.
Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 61st largest by planned enrollment of the 109 interventional ones that give a count, is one of 11 that started in 2023, is one of 27 in phase 2, reaches primary completion later than 34 of the 72 other live ones, and was the 60th registered.
276 studies on the registry are indexed under Glomerulonephritis, IGA; 107 are open to participants now.
Browse Glomerulonephritis, IGA studies →57 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:
Hong Zhang · Sites in China
Ages 18–75
Novartis Pharmaceuticals · Sites in China, United States, Colombia and 5 more countries
Ages 2–18
Chengdu Suncadia Medicine Co., Ltd. · Sites in China
Ages 18+
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–75
ADARx Pharmaceuticals, Inc. · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 34 · Phase 3 27 · Phase 4 15
First in 2002; this study’s year is marked. 11 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.
Median enrollment 84 across the 109 interventional studies, 537 across the 18 observational. Of the 35 that completed or were terminated, 4 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 127 have an industry lead sponsor. The 10 most frequent:
Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.
Keymed Biosciences Co.Ltd has 2 studies filed under Glomerulonephritis, IGA — fewer than ten, so there is no comparison to draw.
22 of the studies in Glomerulonephritis, IGA with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06819826Phase 3Biocity Biopharmaceutics Co., Ltd.A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria | 2026-12-31 |
| NCT06935357Phase 3BiogenA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | 2027-05-31 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT07014826Phase 3Chengdu Suncadia Medicine Co., Ltd.A Trial of HRS-5965 Capsule in Primary IgA Nephropathy | 2027-10 |
| NCT02954419Sun Yat-sen UniversityIgA Nephropathy Biomarkers Evaluation Study (INTEREST) | 2026-11 |
Add all 22 to your calendar (.ics) → With an account.
Among the 127 studies in Glomerulonephritis, IGA with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin A(IgA) nephropathy.
In 1968, immunoglobulin A nephropathy (IgAN) was developed by French pathologist Dr. Jean Berger and his colleague Dr. Nicole Hinglais that what is described as glomerular "immunoglobulin A (IgA)-immune globule" - immune globule Protein G (IgG) intercapillary deposition" of kidney disease, the main pathological feature of which is on the glomerulus IgA deposition, usually accompanied by local cell proliferation and stromal dilation. Since there is not enough specificity and spirit Biomarkers of sensitivity, the only way to confirm the diagnosis is renal biopsy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CM338 will be injected subcutaneously.
Biological: CM338
CM338 will be injected subcutaneously.
Biological: CM338
CM338 will be injected subcutaneously.
Biological: CM338
CM338 injection
The incidence of adverse events of CM338 in subjects with immunoglobulin A nephropathy
To evaluate the incidence of adverse events, including abnormalities of laboratory examination, physical examination, vital signs, 12-lead electrocardiogram (12-ECG) and others.
Time frame: up to week 112
Started May 2023 (actual). Primary completion is estimated for Jun 2027, 49 months after the start.
Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 49 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CM338